

# **SUPPLEMENTAL MATERIAL**

**Table S1. Characteristics of the hospitals included in the registry.**

<b>Hospital characteristics</b>	<b>n(%)</b>
Hospital location	
- Urban	80 (90.9)
- Rural	3 (3.3)
- Unknown	5 (5.8)
Hospital type	
- Teaching	71 (80.6)
- Non-teaching	12 (13.6)
- Unknown	5 (5.8)
Hospital size	
- Large ( $\geq 400$ )	43 (48.9)
- Medium (100-399)	34 (38.6)
- Small ( $< 100$ )	11 (12.5)
ICU bed size	
- $< 25$	4 (4.6)
- 25-50	8 (9.1)
- $> 50$	17 (19.3)
- Unknown	59 (67)

**Table S2. Baseline characteristics supplement.**

Variables	Total cohort	Non-ICU patients			ICU patients		
		Without cardiac arrest	With cardiac arrest	P-value	Without cardiac arrest	With cardiac arrest	P-value
<b>Race n(%)</b>		5946	134		2063	375	
Native American	34 (0.4)	18 (0.3)	0	-	14 (0.7)	2 (0.5)	0.10
Asian	463 (5.5)	322 (5.4)	1 (0.7)	<b>0.02</b>	122 (5.9)	18 (4.8)	0.39
Pacific islander	23 (0.3)	17 (0.3)	0	-	5 (0.2)	1 (0.3)	0.93
Not documented	657 (7.7)	504 (8.5)	16 (11.9)	<b>0.16</b>	100 (4.8)	37 (9.9)	<b>&lt;0.001</b>
<b>Prior medication use</b>							
- Statin use	2891 (97.3)	1966 (33.1)	54 (40.3)	0.37	710 (34.4)	161 (42.9)	0.99
- ACE/ARB use	2191 (53.3)	1471 (24.7)	36 (26.9)	0.38	564 (27.3)	120 (32)	0.33
- Mineralocorticoid antagonist	42 (1.02)	28 (0.5)	1 (0.7)	0.99	12 (0.6)	1(0.3)	0.63
- Aspirin only	1752 (82.8)	1185 (19.9)	42 (31.3)	0.99	451 (21.9)	74 (19.7)	0.28
- Anticoagulant	1064 (13)	694 (11.7)	31 (23.1)	<b>&lt;0.001</b>	283 (13.7)	56 (14.9)	0.88
- Insulin use	1066 (47.2)	687 (11.6)	24 (17.9)	0.26	285 (13.8)	70 (18.7)	0.77
- Steroid use (inhaled/ oral)	1025 (12)	644 (10.8)	13 (9.7)	0.78	315 (15.3)	53 (14.1)	0.63
- Non steroid immunosuppressive /chemotherapy	395 (4.6)	262 (4.4)	6 (4.5)	0.99	106 (5.1)	21 (5.6)	0.81
- Hydroxychloroquine	409 (4.8)	262 (4.4)	7 (5.2)	0.81	122 (5.9)	18 (4.8)	.46
<b>Past medical history</b>							
- Peripheral artery disease	225 (2.6)	141 (2.4)	5 (3.7)	0.46	64 (3.1)	15 (4)	0.46
- Hyperlipidemia	2932 (34.4)	1944 (32.7)	49 (36.6)	0.39	798 (38.7)	141 (37.6)	0.74
- Chronic pulmonary disease	1381 (16.2)	906 (15.2)	20 (14.9)	0.99	388 (18.8)	67 (17.9)	0.72
- Smoking or e-cigarette (vaping)	533 (6.3)	350 (5.9)	11 (8.2)	0.35	140 (6.8)	32 (8.5)	0.27
<b>Associated diagnoses during hospitalization</b>							
- Supraventricular arrhythmia	89 (1.1)	17 (0.3)	1 (0.7)	0.86	31 (1.5)	40 (10.7)	<b>&lt;0.001</b>
- Atrial fibrillation	699 (8.2)	321 (5.4)	24 (17.9)	<b>&lt;0.001</b>	272 (13.2)	82 (21.9)	<b>&lt;0.001</b>
- Acute MI/PCI	51 (0.59)	10(0.2)	1 (0.7)	0.44	29 (1.4)	11 (2.9)	<b>0.004</b>
- In-hospital shock	1057 (12.9)	54 (0.9)	30(22.4)	<b>&lt;0.001</b>	706 (34.2)	267 (71.2)	<b>&lt;0.001</b>
- New onset heart failure	127 (1.5)	34 (0.6)	2 (1.5)	0.42	58 (2.8)	33 (8.8)	<b>&lt;0.001</b>
- Myocarditis	28 (0.33)	8 (0.1)	0	1.0	10 (0.5)	10 (2.7)	<b>0.004</b>

- PE/DVT	280 (3.29)	80 (1.3)	2 (1.5)	1.0	169 (8.2)	29 (7.7)	0.85
- Clinical bleeding requiring transfusion	255 (3)	61 (1)	3 (2.2)	0.35	147 (7.1)	44 (11.7)	<b>0.004</b>
- New Hemodialysis or CRRT	334 (3.9)	13 (0.20)	0	1.0	233 (11.3)	88 (23.5)	<b>&lt;0.001</b>
- Ischemic or hemorrhagic stroke	104 (1.2)	26 (0.4)	0	0.92	58 (2.8)	20 (5.3)	<b>0.02</b>
<b>Baseline laboratory</b>							
- Mean Serum Creatinine (mg/dl) (SD)		1.72 (6.19)	2.42 (2.31)	<b>&lt;0.001</b>	1.94 (4.42)	2.40 (5.56)	<b>&lt;0.001</b>
- Troponin (ng/ml)		4.51 (21.96)	34.96 (60.29)	<b>&lt;0.001</b>	3.96 (26.47)	13.67 (58.81)	<b>&lt;0.001</b>
<b>Management prior to cardiac arrest</b>							
- Inotropes	720 (8.5)	39 (0.7)	9 (6.7)	<b>&lt;0.001</b>	644 (31.2)	28 (7.5)	<b>&lt;0.001</b>
- Mechanical ventilation	1496 (17.6%)	76 (1.3)	11 (8.2)	<b>&lt;0.001</b>	1305 (63.3)	104 (27.7)	<b>&lt;0.001</b>
- Glucocorticoid	1703 (21.6)	821 (13.8)	17 (12.7)	0.97	712 (34.5)	153 (40.8)	<b>&lt;0.001</b>
- Hydroxychloroquine	3723 (44.9)	2411 (40.6)	69 (51.5)	<b>0.004</b>	1039 (50.4)	203 (54.1)	<b>0.02</b>
- Remdesivir	654 (7.9)	350 (5.9)	3 (2.2)	0.10	273 (13.2)	28 (7.5)	<b>0.002</b>

**Table S3. Discharge location of patients with cardiac arrest.**

<b>Discharge location</b>	<b>N (%)</b>
Discharged home	11 (2.2)
Hospice	1 (0.2)
Acute care facility	6 (1.2)
Other health care facility	15 (2.9)
AMA	1 (0.2)

**Table S4. Predictors of survival to discharge in patients with cardiac arrest.**

<b>Variables</b>	<b>Odds ratio</b>	<b>Confidence Interval</b>	<b>P-value</b>
Age group (compared to <50)			
- 50-59	0.69	0.21-2.14	0.49
- 60-69	2.04	0.59-6.98	0.26
- 70-79	5.69	1.26-25.71	<b>0.02</b>
- ≥80	21.67	2.19-214.63	<b>0.008</b>
Sex (Female compared to male)	1.20	0.52-2.77	0.66
Race (reference non-Hispanic whites)			
- Hispanic	2.13	0.76-5.94	0.15
- Non-Hispanic Black	2.28	0.81-6.45	0.12
BMI category (≥30 compared to <30)	1.13	0.38-5.11	0.77
Severity score			
qSOFA	2.35	0.58-0.51	0.23
Comorbidities			
- Prior MI/ PCI or CABG	4.27	0.14-1.34	0.14
- Hypertension	0.29	0.09-1.01	0.90
- Hyperlipidemia	0.85	0.37-1.97	0.71
- Congestive heart failure	1.06	0.31-3.61	0.93
- Chronic kidney disease/ESRD	1.47	0.50-4.37	0.48
- Diabetes	0.85	0.38-1.91	0.70
- Chronic lung disease	1.06	0.35-3.21	0.91
- Smoker/ e-cigarette user	2.25	0.45-11.16	0.32

Figure S1. Distribution of total cohort by state.




Figure S2. Incidence of in-hospital cardiac arrest (IHCA) and survival to discharge among patients with IHCA according to hospital characteristics.

